炎症性储袋并发症的药物治疗更新
本文综述了回肠储袋肛管吻合术(IPAA)后炎症性并发症的药物治疗,重点讨论慢性储袋炎及储袋克罗恩病的诊断与内科管理,包括新型生物制剂的应用进展。
要点
- 储袋炎是IPAA术后最常见的远期并发症,多数经抗生素治疗有效。
- 抗生素无效的慢性储袋炎需排查继发病因,包括储袋克罗恩病。
- 新型生物制剂为慢性储袋炎和储袋克罗恩病提供了更多治疗选择。
核心结论
- 慢性储袋炎和储袋克罗恩病是IPAA术后重要炎症并发症,需考虑继发病因并合理使用生物制剂。
研究设计与样本
- 本文为叙述性综述,聚焦回肠储袋炎症性并发症的诊断与内科管理。
主要发现
- IPAA术后多数患者功能结果良好,但储袋炎是最常见的远期并发症。
- 多数储袋炎对抗生素治疗有反应,部分患者发展为慢性储袋炎,导致显著疾病负担和偶发储袋失败。
- 常规抗菌治疗无效的储袋炎患者需考虑慢性储袋炎的继发病因,包括储袋克罗恩病。
- 近年关于慢性储袋炎和储袋克罗恩病的内科治疗文献增多,包括新型生物制剂的使用。
临床怎么用
- 对IPAA术后储袋炎患者,首先评估抗生素治疗反应,无效时排查继发病因如储袋克罗恩病。
- 慢性储袋炎和储袋克罗恩病的内科管理可考虑新型生物制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Total proctocolectomy with ileal pouch-anal anastomosis is the surgical procedure of choice for patients with medically-refractory ulcerative colitis or ulcerative colitis with associated dysplasia. Although most patients after ileal pouch-anal anastomosis experience good functional outcomes, a number of complications may develop. Of the long-term complications, pouchitis is most common. Although most respond to antibiotic treatment, some patients develop chronic pouchitis, leading to substantial morbidity and occasionally pouch failure. In patients with pouchitis who are not responsive to conventional antimicrobial therapy, secondary causes of chronic pouchitis need to be considered, including Crohn's disease of the pouch. In recent years, more literature has become available regarding the medical management of chronic pouchitis and Crohn's disease of the pouch, including the use of newer biologic agents. We herein provide a concise review on inflammatory complications involving the ileal pouch, including a focused approach to diagnosis and medical management.
引用
- Quinn KP, Raffals LE. An Update on the Medical Management of Inflammatory Pouch Complications. Am J Gastroenterol. 2020. PMID: 32453044. doi:10.14309/ajg.0000000000000666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。